Notice Number: NOT-DA-06-022

Key Dates
Release Date: July 5, 2006

Issued by
National Institute on Drug Abuse (NIDA) (http://www.nida.nih.gov)

Purpose

Synopsis No. N01DA-5-8853
National Institute on Drug Abuse
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, MD  20892-9551

The National Institute on Drug Abuse (NIDA) plans to solicit proposals from qualified organizations having in-house capability to perform in vivo rodent and primate pharmacology studies of new drugs of abuse and potential pharmacotherapies for drug dependence disorders.  Primate studies will include the evaluation of test compound effects in opiate-dependent monkeys.  Contractor-generated data on new drugs of abuse will be provided to the DEA by NIDA.  Contractor-generated data on potential pharmacotherapies will be used by the NIDA Medications Development Program.  The Contractor will be blinded to the identity of proprietary test compounds and all compounds will be evaluated in established assays, as specified by the NIDA Project Officer.  In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances.  All offerors must be in compliance with the NIH guidelines on the care and use of laboratory animals and, the laboratory must be operated according to the FDA’s Good Laboratory Practices Program.

We anticipate the award of one cost reimbursement contract for a period of five years.  The contract will include additional options to cover increased quantities.  RFP No. N01DA-7-8859 will be available electronically on or about July 18, 2006.  You will access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html).   All information required for the submission of an offer will be contained in or accessible through the electronic RFP package.  Response to the RFP will be due on or about September 15, 2006.  NIDA will consider proposals submitted by any responsible offeror.  This advertisement does not commit the Government to award a contract.  See Note 26.

Point of Contact:

Pedro M. Godinez, Contracting Specialist
National Institute on Drug Abuse, NIH
NIDA R&D Contracts Management Branch
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, Maryland  20892-8402
E-mail: pg186o@nih.gov
Telephone: (301) 443-6677
Fax:  (301) 443-7595

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.